$BLPH Bellerophon Therapeutics, Inc. Insiders
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Bellerophon Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of current and past insiders in Bellerophon Therapeutics, Inc.. Find out how many shares they currently own, their value and whether they buy or sell their shares.
Bellerophon Therapeutics, Inc. Insiders
| Name | Position | Total Shares | Current Value ($) | Last 3 Months | Buy / Sell | Last Transaction | |
|---|---|---|---|---|---|---|---|
| Abrams David | Treasurer | 13,116 | 8,657 | Dec 03 2015 | |||
| Agrawal Amit | Chief Operating Officer | 0 | 0 | Jul 13 2015 | |||
| Amin Naseem | Director | 1,818,867 | 1,200,452 | Sep 14 2020 | |||
| ARCH VENTURE FUND VI LP | 10% Owner | 965,660 | 637,336 | Feb 23 2015 | |||
| BENNETT MATTHEW | Director | 30,552 | 20,164 | Sep 14 2020 | |||
| Bruder Scott P | Director | 18,692 | 12,337 | Sep 14 2020 | |||
| Cloyd Mary Ann | Director | 21,858 | 14,426 | Sep 14 2020 | |||
| Dekker Martin | VP of Engineering & Manuf | 124,619 | 82,249 | Nov 19 2019 | |||
| Edmonds Amy | VP Clinical Operations & Admin | 140,216 | 92,543 | Sep 30 2019 | |||
| FARES Wassim | Chief Medical Officer | 4,000 | 2,640 | Sep 14 2020 | |||
| Fernandes Peter | Chief Regulatory & Safety Offr | 182,022 | 120,135 | Nov 19 2019 | |||
| Heyrman Reinilde | Chief Clinical Dev. Officer | 9,483 | 6,259 | Mar 16 2015 | |||
| Holt Matthew S. | Director | 18,232 | 12,033 | Jun 21 2016 | |||
| Huennekens R Scott | Director | 0 | 0 | May 14 2015 | |||
| Korner Assaf | CFO | 66,078 | 43,611 | Nov 19 2019 | |||
| Linde North America, Inc. | 10% Owner | 1,629,804 | 1,075,671 | Feb 23 2015 | |||
| Luehring Jens | Director | 95,213 | 62,841 | Jun 25 2018 | |||
| MEGLASSON MARTIN | Chief Scientific Officer | 19,098 | 12,605 | May 22 2015 | |||
| MEGLASSON MARTIN | Chief Scientific Officer | 0 | 0 | Feb 19 2015 | |||
| Moura Andre V. | Director | 68,736 | 45,366 | Sep 14 2020 | |||
| Naidu Manesh | Chief Business Officer | 11,319 | 7,471 | Mar 16 2015 | |||
| NELSEN ROBERT | Director | 965,660 | 637,336 | Feb 23 2015 | |||
| New Mountain Investments II, LLC | 10% Owner | 609,231 | 402,092 | Mar 22 2021 | |||
| Peacock Jonathan M | Director | 157,033 | 103,642 | Apr 02 2021 | |||
| Puissance Cross-Border Opportunities III LLC | 10% Owner | 0 | 0 | Apr 20 2020 | |||
| Puissance Life Science Opportunities Fund VI | 10% Owner | 1,763,077 | 1,163,631 | Apr 26 2021 | |||
| Quinn Deborah | Chief Medical Officer | 94,070 | 62,086 | Jun 14 2018 | |||
| Schoeps Megan | Principal Financial Officer | 19,248 | 12,704 | Dec 13 2017 | |||
| Shah Parag Suresh | VP of Business Operations | 105,606 | 69,700 | Nov 19 2019 | |||
| Tasse Daniel | Director | 182,604 | 120,519 | Jun 25 2018 | |||
| Tenenbaum Fabian | Chief Executive Officer | 407,459 | 268,923 | Nov 19 2019 | |||
| Teufel Crispin | Director | 0 | 0 | Sep 14 2020 | |||
| VENROCK ASSOCIATES IV L P | 10% Owner | 6,824,425 | 4,504,121 | Oct 28 2019 | |||
| Wang Theodore T | Director | 58,313 | 38,487 | Sep 14 2020 | |||
| Weinstein Adam | Director | 42,130 | 27,806 | Sep 26 2017 |